Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28278904 | 0.85 | HTR2A (0.44) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL556764 | 0.82 | PARP1 (0.51) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL7856329 | 0.82 | HTR2A (0.43) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL1272724 | 0.81 | PARP1 (0.44) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL7576839 | 0.81 | PARP1 (0.50) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL3823364 | 0.81 | PARP1 (0.46) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL1647056 | 0.81 | PARP1 (0.46) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL20138342 | 0.81 | PARP1 (0.46) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL23733959 | 0.80 | GABRA1 (0.44) | PARP1HTR2AHTR2CBRD4HTR1A | |
| SCHEMBL2142149 | 0.80 | ALDH1A1 (0.53) | PARP1HTR2AHTR2CBRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4310087-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023196875-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11066414-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5731472-A | HETEROCYCLIC NITROGEN COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0480939-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
| US-3988155-A | CYANINE SENSITIZING DYES | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-26 | — | — | US | disclosed |
| US-3985563-A | Silver halide photographic emulsion | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PARP1 2914/4885HTR2A 4646/4885HTR2C 4653/4885 |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | PARP1 1381/4885HTR2A 2432/4885HTR2C 3023/4885 |
| US-11066414-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | PARP1 1381/4885HTR2A 2432/4885HTR2C 3023/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PARP1 2914/4885HTR2A 4646/4885HTR2C 4653/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | PARP1 2414/4885HTR2A 1013/4885HTR2C 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.